Published March 2019
| Version v1
Journal article
Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420
Creators
- 1. University of Pittsburgh Medical Center, University of Pittsburgh Physicians, Department of Neurology, Department of Medicine, Pittsburgh (United States)
- 2. Merck & Co, Kenilworth, New Jersey (United States)
- 3. University of Wisconsin, Madison (United States)
- 4. Washington University School of Medicine, St Louis (United States)
- 5. Emory University, Atlanta (Georgia)
Description
To evaluate the toxicity and efficacy of adjuvant temozolomide (TMZ) and irinotecan (CPT-11) for 12 months after concurrent chemoradiation in patients with newly diagnosed glioblastoma (GBM).
Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2018.11.008;
- PII
- S0360301618339555;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 103
- Journal Issue
- 4
- Journal Page Range
- p. 878-886
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 55057244
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- DIAGNOSIS; GLIOMAS; PATIENTS; RADIOTHERAPY; THERAPEUTIC DOSES; TOXICITY
- Descriptors DEC
- DISEASES; DOSES; MEDICINE; NEOPLASMS; NERVOUS SYSTEM DISEASES; NUCLEAR MEDICINE; RADIOLOGY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2018 Published by Elsevier Inc.